
MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (USD)

The MSCI ACWI IMI Genomic Innovation Select Screened 100 Index is based on the MSCI ACWI IMI Index, its parent index, and includes large, mid and small-cap securities across 23 Developed Markets (DM) and 20 Emerging Markets (EM) countries*. The Index aims to represent the performance of a set of companies that are expected to derive significant revenues, based on the underlying index methodology criteria, from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology while excluding those involved in certain controversial businesses or with relatively low ESG Ratings.

For a complete description of the index methodology, please see Index methodology - MSCI.

CUMULATIVE INDEX PERFORMANCE — PRICE RETURNS (USD) (NOV 2010 – JUN 2025)



ANNUAL PERFORMANCE (%)

Year	MSCI ACWI IMI Genomic Innovation Select Screened 100	MSCI ACWI IMI
2024	-2.58	14.61
2023	-3.87	19.48
2022	-31.96	-19.84
2021	-1.04	16.52
2020	45.61	14.36
2019	33.38	23.86
2018	-8.01	-11.79
2017	29.84	21.66
2016	-14.64	6.18
2015	9.29	-4.03
2014	22.91	1.85
2013	53.35	21.07
2012	14.44	13.77
2011	-5.13	-9.87

INDEX PERFORMANCE - PRICE RETURNS (%) (JUN 30, 2025)

					ANNUALIZED			
	1 Mo	3 Мо	1 Yr	YTD	3 Yr	5 Yr	10 Yr	Since Nov 30, 2010
MSCI ACWI IMI Genomic Innovation Select Screened 100	5.32	1.10	-5.19	-3.65	-3.91	-5.92	0.84	7.65
MSCI ACWI IMI	4.40	11.05	14.15	8.86	14.88	11.58	7.77	7.64

INDEX RISK AND RETURN CHARACTERISTICS (JUN 30, 2025)

		ANNUALIZED STD DEV (%) 2			SHARPE RATIO 2,3				MAXIMUM DRAWDOWN		
	Turnover (%) 1	3 Yr	5 Yr	10 Yr	3 Yr	5 Yr	10 Yr	Since Nov 30, 2010	(%)	Period YYYY-MM-DD	
MSCI ACWI IMI Genomic Innovation Select Screened 100	32.90	18.85	20.00	21.75	-0.36	-0.34	0.06	0.38	54.26	2021-09-06—2025-04-08	
MSCI ACWI IMI	2.24	14.93	15.51	15.15	0.70	0.61	0.44	0.48	34.68	2020-02-12-2020-03-23	

¹ Last 12 months ² Based on monthly price returns data



³ Based on NY FED Overnight SOFR from Sep 1 2021 & on ICE LIBOR 1M prior that date


MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (USD)

INDEX CHARACTERISTICS


TOP 10 CONSTITUENTS

	Country	Float Adj Mkt Cap (USD Billions)	Index Wt. (%)
NATERA	US	80.18	4.68
LONZA GROUP	CH	76.69	4.48
AGILENT TECHNOLOGIES	US	76.27	4.46
ABBOTT LABORATORIES	US	73.78	4.31
ABBVIE	US	73.64	4.30
DANAHER CORP	US	73.25	4.28
VERTEX PHARMACEUTICALS	US	73.01	4.27
ROCHE HOLDING GENUSS	CH	71.67	4.19
BRISTOL-MYERS SQUIBB CO	US	70.92	4.14
ILLUMINA	US	68.70	4.01
Total		738.11	43.13

SUB-INDUSTRY WEIGHTS



COUNTRY WEIGHTS



The MSCI ACWI IMI Genomic Innovation Select Screened 100 Index was launched on Sep 16, 2021. Data prior to the launch date is back-tested test (i.e. calculations of how the index might have performed over that time period had the index existed). There are frequently material differences between back-tested performance and actual results. Past performance — whether actual or back-tested — is no indication or guarantee of future performance.



^{*}DM countries include: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, the UK and the US. EM countries include: Brazil, Chile, China, Colombia, Czech Republic, Greece, Hungary, Indonesia, Korea, Malaysia, Mexico, Peru, Philippines, Poland, Qatar, South Africa, Taiwan, Thailand, Turkey and United Arab Emirates.

The MSCI ESG Screened Indexes were renamed the MSCI Screened Indexes as of Feb 3, 2025.

JUN 30, 2025 Index Factsheet

ABOUT MSCI

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.

The information contained herein (the "Information") may not be reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create any derivative works, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics and Real Estate are products of MSCI Inc. that utilize information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN MAKING OR COMPILING THE INFORMATION (EACH, AN "INFORMATION PROVIDER") MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH INFORMATION PROVIDER HEREBY EXPRESSLY DISCLAIMS ALL IMPLIEDWARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE WITHOUT LIMINING ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY OR SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited. Privacy no

© 2025 MSCI Inc. All rights reserved.

